IVZ Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Invesco Ltd (IVZ) is not a clear buy right now for a beginner long-term investor with $50,000-$100,000, even though the stock has positive medium-term support from analyst price target raises and a bullish options skew. The technical setup is mixed: the moving averages are bullish, but MACD remains negative and the stock is already near resistance around $28.28-$28.81, which limits immediate upside from the current pre-market price of $27.60. Because the user is impatient and does not want to wait for a better entry, this is still not an ideal buy today; the better call is to hold and wait for a cleaner breakout or a pullback entry.
IVZ is in a short- to medium-term uptrend based on bullish moving averages (SMA_5 > SMA_20 > SMA_200). However, momentum is not fully supportive: MACD histogram is below zero and negatively contracting, which suggests upside momentum is weakening. RSI_6 at 68.33 is elevated and close to overbought territory, so the stock may be stretched near term. The current pre-market price of 27.60 is above the pivot at 27.423 and close to R1 at 28.278, making resistance a near-term obstacle. Overall trend is constructive, but the current entry is not especially attractive for a beginner long-term buyer.
Analysts broadly raised price targets after Q1 results, with several firms improving targets to the $28-$32 range. TD Cowen was notably constructive, citing flow and operating margin improvements, while Goldman Sachs highlighted stronger organic fee growth, margin expansion potential, and improving balance sheet flexibility. Congress trading data also shows one recent purchase and no sales, which is a positive sentiment signal. The bullish options skew and constructive longer-term margin/flow narrative are additional positives.
No news was reported in the recent week, so there is no fresh catalyst driving the stock now. Hedge funds have been selling aggressively, with selling up 14,710.43% over the last quarter, which is a meaningful negative institutional sentiment signal. Argus downgraded the stock to Hold from Buy due to the large run-up in the share price and potential competition for the QQQ franchise. Competition from new ETF entrants and pressure on economics remain key concerns, and JPMorgan also cut its target recently before later target raises elsewhere. The stock trend model suggests only modest near-term gains, with a high probability of a slight next-day decline.
Latest quarter season: Q1 earnings. The company appears to have delivered an operating income beat, helped by expense management, and analysts pointed to better flows and improved operating margins. However, Morgan Stanley noted it reduced its 2026 EPS estimate by 7.7% to $2.48 due to lower net revenue yield, which offsets some of the improvement. Overall, the latest quarter looked operationally constructive, but not enough to remove longer-term margin and competition concerns.
Analyst sentiment is mixed but slightly positive. Several firms raised price targets after Q1, including Morgan Stanley to $28, Evercore to $28, JPMorgan to $27.50, TD Cowen to $32, Goldman Sachs to $30, Barclays to $26, and RBC to $31. The trend shows improving target levels, but ratings remain mostly Neutral/Equal Weight/In Line, with only TD Cowen and RBC clearly bullish. The Wall Street pros view is that Invesco has better flow and margin potential, while the cons view is that valuation has already rerated, competition for QQQ is rising, and the stock may be more fairly valued after its strong run.
